CLINICAL RESEARCH: GENETICS AND CORONARY ARTERY DISEASE
Polymorphism in KIF6 Gene and Benefit From Statins After Acute Coronary SyndromesResults From the PROVE IT-TIMI 22 Study
Olga A. Iakoubova, MD, PhD*,*,
Marc S. Sabatine, MD, MPH, FACC ,
Charles M. Rowland, MS*,
Carmen H. Tong, BS*,
Joseph J. Catanese, BS*,
Koustubh Ranade, PhD ,
Katy L. Simonsen, PhD,
Todd G. Kirchgessner, PhD,
Christopher P. Cannon, MD, FACC,
James J. Devlin, PhD* and
Eugene Braunwald, MD, MACC
* Celera, Alameda, California
TIMI Study Group, Cardiovascular Division, Brigham & Women’s Hospital, Harvard Medical School, Boston, Massachusetts
Pharmaceutical Research Institute, Bristol-Myers Squibb, Princeton, New Jersey.
Manuscript received August 13, 2007;
revised manuscript received September 28, 2007,
accepted October 22, 2007.
* Reprint requests and correspondence: Dr. Olga A. Iakoubova, Celera, Inc., 1401 Harbor Bay Parkway, Alameda, California 94502. (Email: olga.iakoubova{at}celera.com).
Objectives: We explored whether the benefit of intensive versus moderate statin therapy would be greater in carriers of KIF6 719Arg than in noncarriers.
Background: The 719Arg variant of Trp719Arg (rs20455), a polymorphism in kinesin-like protein 6, is associated with greater risk of coronary events and greater benefit from pravastatin versus placebo.
Methods: We genotyped 1,778 acute coronary syndrome patients within the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy: Thrombolysis in Myocardial Infarction 22) trial and investigated different intensities of statin therapy in carriers of 719Arg and in noncarriers using Cox proportional hazards models that adjusted for traditional risk factors.
Results: Benefit from intensive, compared with moderate, statin therapy was significantly greater in the 59% of the cohort who were carriers (hazard ratio [HR] 0.59, 95% confidence interval [CI] 0.45 to 0.77) than in those who were noncarriers (HR 0.94, 95% CI 0.70 to 1.27; p = 0.018 for interaction between 719Arg carrier status and treatment). Absolute risk reduction was 10.0% in carriers versus 0.8% in noncarriers. The benefit of intensive therapy in carriers was significant as early as day 30 of therapy. Carriers and noncarriers did not differ in on-treatment low-density lipoprotein cholesterol, triglyceride, or C-reactive protein (CRP) levels.
Conclusions: Carriers of 719Arg receive significantly greater benefit from intensive statin therapy than do noncarriers, a superior benefit that appears to be due to a mechanism distinct from lipid or CRP lowering. Functional studies of the KIF6 kinesin are warranted, given the consistent association of Trp719Arg with risk of coronary events and statin benefit.
|
Abbreviations and Acronyms
| | CHD = coronary heart disease | | CI = confidence interval | | CRP = C-reactive protein | | HDL-C = high-density lipoprotein cholesterol | | HR = hazard ratio | | LDL-C = low-density lipoprotein cholesterol |
|
Related Article
-
Surprises of the Genome and "Personalized" Medicine
- Ali J. Marian
J. Am. Coll. Cardiol. 2008 51: 456-458.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
B. J. Arsenault, S. M. Boekholdt, G. K. Hovingh, C. L. Hyde, D. A. DeMicco, A. Chatterjee, P. Barter, P. Deedwania, D. D. Waters, J. C. LaRosa, et al.
The 719Arg Variant of KIF6 and Cardiovascular Outcomes in Statin-Treated, Stable Coronary Patients of the Treating to New Targets and Incremental Decrease in End Points Through Aggressive Lipid-Lowering Prospective Studies
Circ Cardiovasc Genet,
February 1, 2012;
5(1):
51 - 57.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. J. W. Verschuren, S. Trompet, J. A. M. Wessels, H.-J. Guchelaar, M. P. M. de Maat, M. L. Simoons, and J. W. Jukema
A systematic review on pharmacogenetics in cardiovascular disease: is it ready for clinical application?
Eur. Heart J.,
January 2, 2012;
33(2):
165 - 175.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. M. Ridker, J. G. MacFadyen, R. J. Glynn, and D. I. Chasman
Kinesin-Like Protein 6 (KIF6) Polymorphism and the Efficacy of Rosuvastatin in Primary Prevention
Circ Cardiovasc Genet,
June 1, 2011;
4(3):
312 - 317.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. C. Hopewell, S. Parish, R. Clarke, J. Armitage, L. Bowman, J. Hager, M. Lathrop, R. Collins, and MRC/BHF Heart Protection Study Collaborative Group
No Impact of KIF6 Genotype on Vascular Risk and Statin Response Among 18,348 Randomized Patients in the Heart Protection Study
J. Am. Coll. Cardiol.,
May 17, 2011;
57(20):
2000 - 2007.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. B. Damani and E. J. Topol
Emerging Genomic Applications in Coronary Artery Disease
J. Am. Coll. Cardiol. Intv.,
May 1, 2011;
4(5):
473 - 482.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Versmissen, D. M. Oosterveer, M. Yazdanpanah, M. Mulder, A. Dehghan, J. C. Defesche, J. J. P. Kastelein, and E. J. G. Sijbrands
A frequent variant in the ABCA1 gene is associated with increased coronary heart disease risk and a better response to statin treatment in familial hypercholesterolemia patients
Eur. Heart J.,
February 2, 2011;
32(4):
469 - 475.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. L. Assimes, H. Holm, S. Kathiresan, M. P. Reilly, G. Thorleifsson, B. F. Voight, J. Erdmann, C. Willenborg, D. Vaidya, C. Xie, et al.
Lack of Association Between the Trp719Arg Polymorphism in Kinesin-Like Protein-6 and Coronary Artery Disease in 19 Case-Control Studies
J. Am. Coll. Cardiol.,
November 2, 2010;
56(19):
1552 - 1563.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. J. Topol and S. B. Damani
The KIF6 Collapse
J. Am. Coll. Cardiol.,
November 2, 2010;
56(19):
1564 - 1566.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. S. Forrester
Redefining Normal Low-Density Lipoprotein Cholesterol: A Strategy to Unseat Coronary Disease as the Nation's Leading Killer
J. Am. Coll. Cardiol.,
August 17, 2010;
56(8):
630 - 636.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. A. Iakoubova, M. Robertson, C. H. Tong, C. M. Rowland, J. J. Catanese, G. J. Blauw, J. W. Jukema, M. B. Murphy, J. J. Devlin, I. Ford, et al.
KIF6 Trp719Arg polymorphism and the effect of statin therapy in elderly patients: results from the PROSPER study
European Journal of Cardiovascular Prevention & Rehabilitation,
August 1, 2010;
17(4):
455 - 461.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. S. Ginsburg and D. Voora
The Long and Winding Road to Warfarin Pharmacogenetic Testing
J. Am. Coll. Cardiol.,
June 22, 2010;
55(25):
2813 - 2815.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. M. Lipkin, E. C. Chao, V. Moreno, L. S. Rozek, H. Rennert, M. Pinchev, D. Dizon, G. Rennert, L. Kopelovich, and S. B. Gruber
Genetic Variation in 3-Hydroxy-3-Methylglutaryl CoA Reductase Modifies the Chemopreventive Activity of Statins for Colorectal Cancer
Cancer Prevention Research,
May 1, 2010;
3(5):
597 - 603.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. R. Superko, K. Momary, and S. King III
Statins in Acute Coronary Syndromes and Genetic Insight
J. Am. Coll. Cardiol.,
March 23, 2010;
55(12):
1281 - 1282.
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. R. Superko and S. King III
Letter by Superko and King Regarding Article, "Lipid Treatment Assessment Project 2: A Multinational Survey to Evaluate the Proportion of Patients Achieving Low-Density Lipoprotein Cholesterol Goals"
Circulation,
March 9, 2010;
121(9):
e233 - e233.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. L. Mega, D. A. Morrow, A. Brown, C. P. Cannon, and M. S. Sabatine
Identification of Genetic Variants Associated With Response to Statin Therapy
Arterioscler Thromb Vasc Biol,
September 1, 2009;
29(9):
1310 - 1315.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. F.R. Stewart, S. Dandona, L. Chen, O. Assogba, M. Belanger, G. Ewart, R. LaRose, H. Doelle, K. Williams, G. A. Wells, et al.
Kinesin Family Member 6 Variant Trp719Arg Does Not Associate With Angiographically Defined Coronary Artery Disease in the Ottawa Heart Genomics Study
J. Am. Coll. Cardiol.,
April 21, 2009;
53(16):
1471 - 1472.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. S. Plump and P. Y. Lum
Genomics and Cardiovascular Drug Development
J. Am. Coll. Cardiol.,
March 31, 2009;
53(13):
1089 - 1100.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. I. Chasman, G. Pare, and P. M Ridker
Population-Based Genomewide Genetic Analysis of Common Clinical Chemistry Analytes
Clin. Chem.,
January 1, 2009;
55(1):
39 - 51.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. J. Kirk, J. L. Hung, S. R. Horner, and J. T. Perez
Implications of Pharmacogenomics for Drug Development
Exp Biol Med,
December 1, 2008;
233(12):
1484 - 1497.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. P. Giugliano and E. Braunwald
The Year in Non-ST-Segment Elevation Acute Coronary Syndrome
J. Am. Coll. Cardiol.,
September 23, 2008;
52(13):
1095 - 1103.
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Iakoubova, J. Shepherd, and F. Sacks
Association of the 719Arg Variant of KIF6 With Both Increased Risk of Coronary Events and With Greater Response to Statin Therapy
J. Am. Coll. Cardiol.,
June 3, 2008;
51(22):
2195 - 2195.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. J. Marian
Reply
J. Am. Coll. Cardiol.,
June 3, 2008;
51(22):
2195 - 2196.
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Braunwald
The Management of Heart Failure: The Past, the Present, and the Future
Circ Heart Fail,
May 1, 2008;
1(1):
58 - 62.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. J. Marian
Surprises of the Genome and "Personalized" Medicine
J. Am. Coll. Cardiol.,
January 29, 2008;
51(4):
456 - 458.
[Full Text]
[PDF]
|
|
|
|
